Ziprasidon Stada

Ziprasidon Stada

ziprasidone

Manufacturer:

Stada

Distributor:

HK Medical Supplies
/
Health Express
Concise Prescribing Info
Contents
Ziprasidone
Indications/Uses
Schizophrenia. Manic or mixed episodes of moderate severity in bipolar disorder.
Dosage/Direction for Use
Adult Acute treatment of schizophrenia & bipolar mania 40 mg bd, may be adjusted up to max 80 mg bd. Maintenance treatment of schizophrenia Administer at the lowest effective dose. In many cases, 20 mg bd may be sufficient.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Known QT-interval prolongation; congenital long QT syndrome; recent acute MI; uncompensated heart failure; arrhythmias treated w/ class IA & III antiarrhythmic medicinal products. Concomitant treatment w/ medicinal products that prolong the QT interval eg, class IA & III antiarrhythmics, arsenic trioxide, halofantrine, levomethadyl acetate, mesoridazine, thioridazine, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, dolasetron mesilate, mefloquine, sertindole or cisapride.
Special Precautions
Mild to moderate dose-related prolongation of the QT-interval. Neuroleptic malignant syndrome. Tardive dyskinesia & other tardive extrapyramidal syndrome after long-term treatment. Venous thromboembolism. Increased risk of CVA in the dementia population. Increased mortality in elderly people w/ dementia. Not for treatment of dementia-related behavioural disturbances. Patients w/ history of seizures; significant bradycardia; risk factors for stroke. Drug reaction w/ eosinophilia & systemic symptoms (DRESS). Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Moderate influence on the ability to drive & use machines. Patients w/ hepatic insufficiency. Pregnancy & lactation. Neonates exposed to antipsychotics during 3rd trimester of pregnancy are at risk for extrapyramidal &/or w/drawal symptoms following delivery. Elderly.
Adverse Reactions
Sedation, akathisia, extrapyramidal disorder, dizziness. Restlessness; dystonia, parkinsonism, tremor, somnolence, headache; vision blurred; nausea, vomiting, constipation, dyspepsia, dry mouth, salivary hypersecretion; musculoskeletal rigidity; asthenia, fatigue.
Drug Interactions
Additive effect w/ medicinal products that prolong the QT interval eg, class IA & III antiarrhythmics, arsenic trioxide, halofantrine, levomethadyl acetate, mesoridazine, thioridazine, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, dolasetron mesilate, mefloquine, sertindole or cisapride. Caution when co-administered w/ other centrally acting medicinal products & alcohol. Risk for pharmacodynamic interactions (including arrhythmias) w/ lithium.
MIMS Class
Antipsychotics
ATC Classification
N05AE04 - ziprasidone ; Belongs to the class of indole derivatives antipsychotics.
Presentation/Packing
Form
Ziprasidon Stada cap 20 mg
Packing/Price
30's
Form
Ziprasidon Stada cap 40 mg
Packing/Price
30's
Form
Ziprasidon Stada cap 60 mg
Packing/Price
30's
Form
Ziprasidon Stada cap 80 mg
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in